Brodalumab, an anti-interleukin-17 receptor A monoclonal antibody, in axial spondyloarthritis: 68-week results from a phase 3 studyopen access
- Authors
- Kim, Tae-Hwan; Kishimoto, Mitsumasa; Wei, James Cheng-Chung; Jeong, Haeyoun; Nozaki, Akiyo; Kobayashi, Shigeto
- Issue Date
- May-2023
- Publisher
- OXFORD UNIV PRESS
- Keywords
- AS; brodalumab; IL-17 receptor A; non-radiographic axial spondyloarthritis
- Citation
- RHEUMATOLOGY, v.62, no.5, pp.1851 - 1859
- Indexed
- SCIE
SCOPUS
- Journal Title
- RHEUMATOLOGY
- Volume
- 62
- Number
- 5
- Start Page
- 1851
- End Page
- 1859
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/191762
- DOI
- 10.1093/rheumatology/keac522
- ISSN
- 1462-0324
- Abstract
- Objective: To evaluate the long-term efficacy and safety of brodalumab, a fully human anti-interleukin-17 receptor A monoclonal antibody, in patients with axial spondyloarthritis (axSpA). Methods: Patients receiving subcutaneous brodalumab 210 mg during the 16-week double-blind period of this multicentre, phase 3 study conducted across Japan, Korea and Taiwan continued the same during the 52-week open-label extension, whereas patients receiving placebo switched to brodalumab 210 mg at week 16. Efficacy Assessment of SpondyloArthritis International Society (ASAS) 40 and ASAS 20 response rates; change from baseline in AS Disease Activity Score using CRP (ASDAS-CRP)] and safety were evaluated. Results: Overall, 145 patients (brodalumab, n = 77; placebo, n = 68) received brodalumab during the open-label extension. ASAS 40 response rates (95% CI) of 56.3% (44.7%, 67.3%) and 57.4% (44.1%, 70.0%) were achieved in the brodalumab and placebo groups, respectively, at week 68. ASAS 20 response rates (95% CI) achieved at week 68 in both treatment groups were similar [brodalumab, 71.3% (60.0%, 80.8%); placebo, 78.7% (66.3%, 88.1%)]. The least squares mean change (95% CI) in ASDAS-CRP at week 68 suggested a clinically important improvement (change, >= 1.1) in both treatment groups [brodalumab, -1.528 (-1.737, -1.319); placebo, -1.586 (-1.815, -1.357)]. The exposure-adjusted event rates (per 100 patient-years) for treatment-emergent adverse events (TEAEs) and drug-related TEAEs were 255.9 and 147.9, respectively; nasopharyngitis (35.6) and upper respiratory tract infection (14.7) were the most common TEAEs. Conclusions: Brodalumab demonstrated sustained efficacy and a consistent safety profile in patients with axSpA over 68 weeks.
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.